Currency
  • Loading...
Weather
  • Loading...
Air Quality (AQI)
  • Loading...

Researchers at the University of California, San Francisco, and Berkeley campuses in the United States have demonstrated in laboratory experiments a method for presenting certain tumor antigens that the immune system previously “could not see” on the cell surface. According to the authors of a preprint posted on bioRxiv.org, the approach could eventually expand targets for cancer immunotherapy, including against tumors that are difficult to treat. The findings have not yet undergone independent peer review, and clinical application remains a distant prospect; the work is early-stage and based on laboratory cell experiments, not on patients.

Key Takeaways: In a screen of nearly 3,000 medicines approved for medical use, the scientists found that the anticancer drug pazopanib can tightly hold a molecule carrying a mutated fragment of the KRAS G12V protein. The method was also applied to regions of the p53 protein where mutations are most common; in experiments, targeted antigens were displayed on the cell surface while the overall recognition profile for normal, healthy proteins remained intact. The data are preprint-only, and safety and efficacy have not been established in clinical trials.

Neoantigens are short peptides and molecular fragments that differ from the body’s usual proteins because of changes in tumor cells. Most tumor neoantigens do not readily form stable complexes with major histocompatibility complex (MHC) proteins, the specialized molecules responsible for displaying antigens on the cell surface. As a result, such antigens are not presented to the immune system and remain effectively “invisible.” The new study builds on the idea of creating additional anchor points that can hold mutated peptides firmly on MHC proteins.

The paper says the researchers first studied the mechanism of action of the drug abacavir, then showed that targeted selection of molecules could create additional anchor points to stabilize the required complex. In work involving KRAS G12V, pazopanib stood out as an exception; for p53, the team used prediction algorithms and computational analysis of gene mutations. In laboratory tests, the researchers also altered the molecules’ structure to reduce effects on T cells: one new derivative retained the ability to stabilize the target complex but weakened T-cell activation far less. The preprint describes laboratory cell assays rather than animal or human studies.

The results point to the prospect of a new generation of safer drugs that could help the immune system fight tumors more effectively, but so far the work involves cell and laboratory experiments. Further steps will require independent verification, animal-model testing, and assessment of toxicity and long-term immune response. Independent groups will need to replicate the findings and determine whether the strategy works in living organisms without triggering unwanted immune reactions. The US-based study may increase interest in broadening targets for cancer immunotherapy, but conclusions about clinical benefit and safety would be premature.

Source: kun.uz